News

News Archive

AstraZeneca to Collaborate with the Harvard Stem Cell Institute in Diabetes AstraZeneca to Collaborate with the Harvard Stem Cell Institute in Diabetes

AstraZeneca have announced that it has entered into a five-year research collaboration with the Harvard Stem Cell Institute (HSCI) to adapt a technique that creates human beta cells from stem cells for use in screens of AstraZeneca’s compound library in the search for new treatments for diabetes. The collaboration also aims to better understand how the function of beta cells declines in diabetes and research findings will be made available to the broader scientific community through peer-reviewed publications.

The Current issue of “The view from here” discusses mitochondrial disorders. The Current issue of “The view from here” discusses mitochondrial disorders.

The topic of this month’s newsletter from Drug Discovery Today is mitochondrial disorders.

MRC Technology Launches Respiratory ‘Call for Targets’ MRC Technology Launches Respiratory ‘Call for Targets’

Project focused on potential small molecule or antibody targets in pathways important in the development or progression of respiratory disease

Cancer Research UK and the Lustgarten Foundation Join with Stand Up To Cancer to Fund New Pancreatic Cancer Dream Team Cancer Research UK and the Lustgarten Foundation Join with Stand Up To Cancer to Fund New Pancreatic Cancer Dream Team

CANCER RESEARCH UK, Stand Up To Cancer (SU2C), and The Lustgarten Foundation have joined forces to fund a Cancer Dream Team Translational Research Grant, and ideas are now being accepted through the American Association for Cancer Research (AACR). The grant provides up to £7.8 million ($12 million) over a three-year period for research on prevention, diagnosis, or treatment of pancreatic cancer by a 'Dream Team' of top scientists. The grant will be a transatlantic collaboration, with Dream Team leaders or principal investigators based in both the United States and the United Kingdom.

Rheumatoid arthritis costs the economy £4.75bn but care still “disgracefully low” with providers challenged by “incoherent reforms” warns leading patient charity and specialist doctors Rheumatoid arthritis costs the economy £4.75bn but care still “disgracefully low” with providers challenged by “incoherent reforms” warns leading patient charity and specialist doctors

Slough (UK) – 4th March 2015: The treatment of rheumatoid arthritis, which costs the NHS £560m annually is not given a high enough priority, partly because government and health service reforms to improve patient outcomes are “incoherent” at a local level, according to a new report.